Jack Allen
Stock Analyst at Baird
(1.48)
# 3,382
Out of 4,898 analysts
42
Total ratings
37.5%
Success rate
-7.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Maintains: Neutral | $0.25 → $1 | $2.39 | -58.16% | 4 | Jun 27, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.14 | +250.88% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.29 | +597.67% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.45 | +121.83% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $40.61 | -1.50% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $69.91 | +51.62% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $11.95 | +50.63% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $24.49 | +634.99% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $1.72 | +365.12% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $56.42 | -7.83% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $35.28 | +138.10% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.64 | +203.03% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.07 | +367.29% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.15 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.43 | +162.39% | 1 | Oct 7, 2021 |
Vor Biopharma
Jun 27, 2025
Maintains: Neutral
Price Target: $0.25 → $1
Current: $2.39
Upside: -58.16%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.14
Upside: +250.88%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.29
Upside: +597.67%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.45
Upside: +121.83%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $40.61
Upside: -1.50%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $69.91
Upside: +51.62%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $11.95
Upside: +50.63%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $24.49
Upside: +634.99%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $1.72
Upside: +365.12%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $56.42
Upside: -7.83%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $35.28
Upside: +138.10%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.64
Upside: +203.03%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.07
Upside: +367.29%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.15
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.43
Upside: +162.39%